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Background: Kinesins play a key role in the development and progression of many human cancers. The present
study investigated the expression and clinical significance of kinesin family member 26B (KIF26B) in colorectal
cancer (CRC).
Methods: Using quantitative real-time PCR and Western blot analyses as well as immunohistochemical staining of a
tissue microarray we examined KIF26B mRNA and protein levels in CRC tumor tissues and paired adjacent normal mucosa.
Moreover, the effect of KIF26B knockdown on CRC cell proliferation was investigated using Cell Counting Kit-8 assays.
Results: Expression of KIF26B was found to be elevated in CRC. Suppression of KIF26B inhibited CRC cell proliferation.
Furthermore, upregulated expression of KIF26B was significantly correlated with tumor size (P = 0.020), American Joint
Committee on Cancer (AJCC) stage (P = 0.018), T stage (P = 0.026), N stage (P = 0.013), and differentiation histology
(P = 0.047). KIF26B was also shown to be an independent prognostic indicator of overall survival for CRC patients
(HR 5.621; 95% CI 2.302–13.730; P < 0.001).
Conclusion: Our data indicate that KIF26B plays an important role in colorectal carcinogenesis and functions as a novel
prognostic indicator and a potential therapeutic target for CRC.
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Colorectal cancer (CRC) is one of the most devastating
malignancies and the third leading cause of cancer mortal-
ity worldwide [1,2]. To date, surgical resection remains the
major treatment for CRC patients [3]. Many improve-
ments have been made in screening, detection and adju-
vant therapy for CRC in recent years [4-6]; however, the
long-term survival associated with this malignancy is not
satisfactory because of tumor recurrence and metastasis
[7,8]. To improve the prognosis of CRC patients, there is a
great need to identify efficient new targets for early diag-
nosis and effective disease management.
The kinesin superfamily proteins (KIFs) are a conserved
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unless otherwise stated.proteins that transport membranous organelles, mRNAs
and proteins to specific destinations [9]. To date, 45 kine-
sins, which are categorized into 14 different families, have
been identified in humans [10]. Kinesins are largely classi-
fied as C-, N- or M-kinesins, which contain their motor
domain at the carboxyl-terminus, at the amino-terminus
or in the intervening region, respectively [11]. In general,
C- and N-kinesins drive microtubule minus end- and plus
end-directed motilities, respectively, while M-kinesins
depolymerize microtubules [12]. N-kinesins are in the ma-
jority [13]. KIFs are involved in many key cellular functions,
including mitosis, meiosis, migration, signal transduction,
microtubule polymer dynamics and intracellular transport
[14]. Accumulating evidence indicates the importance of
KIFs in the regulation of many physiological events, such as
brain function, developmental patterning and tumor sup-
pression [15]. In recent years, many studies have suggested
that KIFs also play an important role in the development orThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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better understanding of the functions of kinesins may facili-
tate the identification of biomarkers for early detection, in-
dications of prognosis and even molecular-targeted therapy
for cancers.
The KIF26B gene, which is located at 1q44, encodes
an N-type kinesin protein. KIF26B along with KIF26A
are two members of the kinesin-11 superfamily. KIF26A
is an unconventional kinesin and plays an important role
in enteric nervous system development by regulating the
GDNF-Ret signaling pathway [18], while KIF26B is a
downstream target of the zinc finger protein Sall1, and
plays an important role in kidney development through
regulating the adhesion of mesenchymal cells in contact
with ureteric buds [19,20]. In the neuronal system, KIF26B
plays a role in the transport of Abelson interactor protein
1 (Abi-1) to different cellular compartments, especially to
the postsynaptic density of excitatory synapses [21]. Re-
cently, it has been reported that overexpression of KIF26B
is associated with poor prognosis in breast cancer [22]. In-
creased amplification of KIF26B is also associated with
higher progression stage of esophageal adenocarcinoma
[23]. Genome-wide copy number analysis revealed that
KIF26B is associated with predisposition to colorectal aden-
oma formation [24]. However, the role of KIF26B in CRC
carcinogenesis and progression remains to be elucidated.
To investigate the expression and clinical significance of
KIF26B in CRC in the present study, we first evaluated
KIF26B expression in CRC specimens and paired adjacent
normal mucosa. We then examined the relationship be-
tween KIF26B expression, clinicopathological features and
patient survival using immunohistochemical analysis of
CRC tissue microarrays. By knockdown the expression of
KIF26B with small hairpin RNA, we also studied the ef-
fects of KIF26B on CRC cell proliferation.
Materials and methods
Patients and specimens
Tissue specimens were collected from 40 CRC patients
(24 male and 16 female; median age, 63.2 y, range 24–88
y) who had undergone tumor resection without receiv-
ing chemotherapy or radiotherapy before surgery at the
General Surgery Department of the Shanghai JiaoTong
University Affiliated Shanghai First People’s Hospital
(China) between November 2013 and March 2014. The
diagnoses were confirmed by two pathologists, and the
tumor staging was based on pathological findings according
to the guidelines of the American Joint Committee on Can-
cer (AJCC) [25]. All the CRC and paired adjacent normal
mucosa specimens were collected in the General Surgery
Department under protocols approved by the Institutional
Review Boards of Shanghai Jiao Tong University Affiliated
Shanghai First People’s Hospital Medical Center. Written
informed consent was obtained from all patients. Thefreshly obtained cancer tissues and adjacent normal mucosa
(10 cm distant from the original tumor site) were immedi-
ately frozen in liquid nitrogen and stored at -80°C prior to
RNA and protein extraction.
Cell lines and plasmids
The established CRC cell lines LoVo, HT29, Caco2, and
RKO were obtained from the Type Culture Collection of
the Chinese Academy of Sciences (Shanghai, China).
The healthy human colon mucosa cell line, NCM460,
was purchased from INCELL (San Antonio, TX, USA).
ALL cell lines were maintained at 37°C under a humidi-
fied atmosphere containing 5% CO2. Cell lines were cul-
tured in DMEM/F12 supplemented with 10% FBS
(Gibco, USA). The short hairpin RNA (shRNA) plasmid
for KIF26B and the control-shRNA plasmid were pur-
chased from Obio Technology (Shanghai, China). For
plasmid transfection, 4 × 104 cells per well in six-plates
were cultured overnight and then transfected with plas-
mids using Lipofectamine 2000 (Invitrogen, CA) as to the
manufacturer’s instructions. Stable clones of RKO and
HT29 cells expressing KIF26BshRNA or control-shRNA
were obtained by puromycin selection. The shRNA target
sequence for KIF26B was: 5′-GCAGCAAACACATTCC
ATACA-3′. The control-shRNA target sequence was: 5′-T
TCTCCGAACGTGTCACGT-3′.
RNA extraction, reverse transcription PCR and
quantitative real-time PCR
Total RNA was prepared from cell cultures, fresh pri-
mary tumors and normal mucosa of 40 CRC patients
using TRIzol reagent (TaKaRa, Japan) according to the
manufacturer’s instructions. First strand cDNA was syn-
thesized from 2 μg of total RNA using RevertAid™First
Strand cDNA Synthesis Kit (Fermentas, USA). For re-
verse transcription PCR, the reaction was performed for
30 cycles of 94°C for 1 min, 55°C for 1 min, 72°C for 1
min, and an additional extension at 72°C for 10 min.
Then, 10 μl of the PCR product was subjected to a 1%
agrose gel electrophoresis with ethidium bromide staining
and quantification was performed with Quantity One soft-
ware (Bio-rad, USA). Quantitative real-time PCR (qRT-
PCR) assays were performed using 4 μl of cDNA (1:10 dilu-
tion) and SYBR green (TaKaRa) in a total volume of 20 μl
using the ABI 7900 Real-time PCR System (ABI, USA).
The amplification protocol used was as follows: 95°C for 2
min, and then 95°C for 10 s, 60°C for 30 s, and 72°C for 30
s, with a final extension at 72°C for 30 s. Relative quantities
(Δ cycle threshold (Ct) values) were obtained by normaliz-
ing to GAPDH. Each reaction was performed in triplicate.




Table 1 Relationship between clinicaopathologic
parameters and KIF26B or Ki67 protein expression (n = 88)
Parameters Total KIF26B P KI67 P
Low High Low High
Age
<65 31 11 20 13 18
≥65 57 24 33 0.544a 30 27 0.338a
Gender
Male 46 17 29 23 23
Female 42 18 24 0.572a 20 22 0.823a
Location
Right 37 12 25 17 20
Others 51 23 28 0.231a 26 25 0.641a
Tumor size (cm)
<5 47 24 23 21 26
≥5 41 11 30 0.020a 22 19 0.401a
AJCC stage
I + II 52 26 26 31 21
III + IV 36 9 27 0.018a 12 24 0.015a
T stage
T1 + T2 9 7 2 8 1
T3 + T4 79 28 51 0.026b 35 44 0.014b
N stage
N0 54 27 27 32 22
N1 + N2 34 8 26 0.013a 11 23 0.014a
M stage
M0 86 34 52 42 44
M1 2 1 1 1.000b 1 1 1.000b
Differentiation
Well + Moderate 78 34 44 38 40
Poor 10 1 9 0.047b 5 5 0.939a
Vascular invasion
No 84 34 50 42 42
Yes 4 1 3 1.000b 1 3 0.617b
aChi-square test.
bFisher’s exact test.
Wang et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:13 Page 3 of 10and antisense 5′-ACTCCTCGTATGCTTTCCGGT-3′;
Ki67, sense 5′-TTCGCAAGCGCATAACCCA-3′ and anti-
sense 5′- AACCGTGTCACAGTGCCAAA-3′; Cyclin D1,
sense 5′-GCTGCGAAGTGGAAACCATC-3′ and anti-
sense 5′-CCTCCTTCTGCACACATTTGAA-3′.
Western blot assays
Total protein was isolated from tissue samples or cultured
cell lines using RIPA lysis buffer (Beyotime Biotechnology,
China) and the protein concentration was measured using
the BCA protein assay kit (Beyotime Biotechnology). Equal
amounts of protein (30 μg) were subjected to 10% sodium
dodecyl sulfate-polyacrylamide gel electrophoresis and then
transferred onto PVDF membranes. Membranes were
blocked in 5% fat-free milk solution containing 0.1%
Tween-20 for 1 h at room temperature. Membranes were
then incubated with primary detection antibody (1:500 dilu-
tion for KIF26B, Abcam, USA; 1:1,000 dilution for GAPDH,
Abgent, USA) at 4°C overnight followed by incubation with
the secondary detection antibody (1:5,000, Abgent) against
rabbit IgG-HRP for 2 h at room temperature. Proteins were
detected using ECL reagent (Pierce Biotechnology, USA).
Quantification based on grayscale analysis was performed
with Quantity One software (Bio-rad, USA).
Immunohistochemistry on tissue microarrays
The tissue microarray (TMA) containing 88 paired CRC
specimens was purchased from Xin Chao Company
(Shanghai, China). Tumors were resected between July
2006 and May 2007. The final follow-up was on August
2012, with a median patient follow-up time for survivors of
46.62 months (range, 3–73 months). The samples were ob-
tained from 46 men and 42 women with a mean age of
68.72 years (range, 24–90 years). Tumor staging was carried
out according to the AJCC staging criteria [25]. Detailed
patient demographic information is shown in Table 1. Sec-
tions were dewaxed in xylene and rehydrated in a graded
series of ethanols, followed by antigen retrieval with 0.01 M
sodium citrate buffer (pH 6.0). Immunohistochemical stain-
ing was performed using the primary antibody against
KIF26B (1:200; Abcam, USA) or Ki67 (1:500; Epitomics,
USA), followed by incubation with the HRP-conjugated
secondary detection antibody (DakoCytomation, Glostrup,
Denmark). Two specialists who were blinded to patient
outcome evaluated the staining independently. For KIF26B,
staining intensity was scored as 0 (negative), 1 (weak), 2
(moderate), and 3 (strong). Staining extent was scored as 0
(0%), 1 (1%–25%), 2 (26%–50%), 3 (51%–75%), and 4
(76%–100%) according to the percentage of positively
stained cells. The final staining score was calculated by
multiplying the staining intensity score by the staining ex-
tent score. According to the final score, the specimens were
divided into two groups: low (0–6), high (7–12). For Ki67,
the percentage of tumor cells that showed nuclear stainingwas assessed. For analysis, a cut-off was set as the median
based on a previous study (24), and the samples were into
low (<46% positive tumor cells) or high (≥46%) groups.
CCK-8 assays
Cell Counting Kit-8 (CCK-8) assays were used to evaluate
cell proliferation according to the manufacturer’s instruc-
tions. Briefly, cells were seeded in 96-well plates (2 × 103
cells/well) in triplicate. At the appropriate time (12, 24, 36,
48, 60, 72, 96 h), the cells were incubated with 10 μl
CCK-8 solution for 2 h at 37°C. Absorbance was mea-
sured at a wavelength of 450 nm on a Gen5 microplate
reader (BioTek, USA).
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For plate colony formation assays, 800 log-phase cells
were seeded in six-well plates and cultured at 37°C
under a humidified atmosphere containing 5% CO2 for 2
weeks. The cells were then fixed with methyl alcohol for
15 min and stained with Giemsa solution for 20 min.
Colonies were then counted and photographed All as-
says were independently performed in triplicate.
Statistical analysis
SPSS version19.0 for Windows (SPSS, Chicago, IL, USA)
was used for all data analysis. For continues variables, data
are expressed as mean ± SD and compared using Student’s
t-test. The association between KIF26B and Ki67 expres-
sion and clinicopathological features was analyzed using
the Pearson’s χ2 or Fisher’s exact tests, when appropriate.
The correlation between KIF26B and Ki67 protein expres-
sion was analyzed using Spearman’s correlation coefficient
test. The Kaplan-Meier method was used to calculate the
overall survival (OS) curves. Cox proportional hazards
models were used in univariate and multivariate analyses
to explore the effects of KIF26B expression and CRC clini-
copathological variables on survival. Variables that showed
a significant prognostic value in univariate analysis were
included in the multivariate analysis model using a back-
ward elimination method. For all tests, a P-value < 0.05
was considered to be statistically significant.
Results
KIF26B expression levels are significantly upregulated in
human colorectal cancer
Forty paired specimens were analyzed for KIF26B
mRNA and protein expression, 30 (75%) colorectal can-
cers showed a more than 2-fold increase in KIF26B
mRNA levels compared with adjacent normal mucosa.
The mean KIF26B mRNA expression was significantly
higher in the 40 tumor tissue specimens compared with
that in the paired adjacent normal mucosa specimens
(4.35 ± 1.33 vs. 2.06 ± 0.86, respectively; P < 0.01, Stu-
dent’s t-test) (Figure 1A–B). Western blot analysis also
showed that KIF26B protein expression was significantly
higher in the 40 tumor tissue specimens compared with
that in the paired adjacent normal mucosa specimens
(2.33 ± 0.07 vs. 0.91 ± 0.04, respectively; P < 0.01, Stu-
dent’s t-test) (Figure 1C–D). KIF26B protein expression
in the RKO, HT29 and LoVo cell lines was higher than
that in the Caco2 and NCM460 cell lines (Figure 1E).
These data indicated that KIF26B expression is com-
monly elevated in human CRC.
Correlation between KIF26B overexpression and
colorectal cancer clinicopathologic factors
KIF26B and Ki67 expression was determined by immu-
nohistochemical analysis of a TMA containing 88 CRCspecimens and paired adjacent normal mucosa. KIF26B
expression was restricted to the cytoplasm with negli-
gible nuclear staining, while Ki67 expression was re-
stricted to the nucleus (Figure 2). Tumors showed
variable (weak, moderate, and strong) KIF26B expres-
sion. High levels of KIF26B expression were detected
in 53 of 88 CRC specimens. Associations of KIF26B
and Ki67 expression with clinicopathological factors
are summarized in Table 1. Upregulated KIF26B ex-
pression was significantly correlated with tumor size
(P = 0.020), AJCC stage (P = 0.018), T stage (P = 0.026),
N stage (P = 0.013), and histological differentiation (P =
0.047). High expression of Ki67 was significantly asso-
ciated with AJCC stage (P = 0.015), T stage (P = 0.014),
and N stage (P = 0.014). Furthermore, in most cases,
tumors with high KIF26B expression showed high Ki67
expression. A positive correlation between KIF26B and
Ki67 on the basis of proliferative activity was identified
by using the Spearman’s correlation coefficient test
(P < 0.01) (Table 2).
Survival analysis and prognostic significance of KIF26B or
Ki67 expression
Kaplan-Meier analysis with a log rank test for OS was
performed to assess the possible association between
tumor expression of KIF26B or Ki67 and patient survival
(Figure 3). Patients with tumors expressing high levels of
KIF26B had a poorer OS (P < 0.001) than patients with
KIF26B-low tumors (Figure 3A), and patients with
Ki67-high tumors had a lower OS (P < 0.001) than pa-
tients with a low Ki67 expression (Figure 3B). Further-
more, with regard to the concomitant expression of
KIF26B and Ki67 proteins, we divided the samples into
three groups as follows: Group 1, tumors exhibiting
both high expression of KIF26B and Ki67; Group 2, tu-
mors with high expression of only one protein; Group 3,
tumors with low expression of both proteins. Notably, a
better OS was observed in Group 3 compared to that of
Group 2, while the poorest OS was observed in Group 1
(P < 0.001) (Figure 3C).
Using a univariate analysis in the Cox proportional
hazards model, a decreased OS was associated with the
following characteristics: tumor location, tumor depth,
AJCC stage, LNM stage, distant metastasis, vascular in-
vasion and the expression of KIF26B and Ki67 (Table 3).
Multivariate analysis revealed that the expression of
KIF26B is an independent prognostic factor for OS (HR
5.621; 95% CI 2.302–13.730; P < 0.001).
Knockdown of KIF26B expression inhibits colorectal
cancer cell proliferation
To further investigate the potential effects of KIF26B on
CRC cell proliferation, we used KIF26B-shRNA to knock-
down expression in transfected RKO and HT29 cell lines.
Figure 2 Immunohistochemical staining for KIF26B and Ki67 expression in CRC cancer. Adjacent normal mucosa showing very weak
KIF26B staining (A, 200×), adjacent normal and tumor tissues showing weak and moderate staining respectively (B, 200×). Strong staining of
KIF26B (C, 200×) in a moderately differentiated colon tumor. Negative control of Ki67 staining (D, 200×) in tumor tissues, Ki67-low staining
(E, 200×) and Ki67-high staining (F, 200×) in tumor tissues.
Figure 1 Expression of KIF26B in human colorectal cancer tissues and cell lines. KIF26B mRNA expression in 40 tumor tissues and paired
adjacent normal mucosa (A). RT PCR analysis of KIF26B mRNA expression in eight paired colorectal tumor tissues (B). Western blot analysis of
KIF26B expression in eight paired colorectal tumor tissues (C). KIF26B protein is higher in tumor tissues than in paired adjacent normal mucosa
(D). KIF26B protein expression in five colorectal cell lines. Grayscale values were evaluated (n = 3, *P <0.05, compared with NCM460 cell line) (E).
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Table 2 The association between KIF26B and Ki67
expression
Tissue sample Ki67 expression P value r
Low High
KIF26B Low 24 11
KIF26B High 19 34 0.002 0.32
Figure 3 Kaplan-Meier plots with log rank test of overall survival (OS
(A) or Ki67 expression levels (B) determined by immunohistochemical stain
tumors expressing high levels of both KIF26B and Ki67 than that in patient
Wang et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:13 Page 6 of 10Control-shRNA plasmids were used as controls and stable
transfected cell lines were obtained by puromycin selec-
tion. The efficacy of KIF26B knockdown was confirmed by
Western blot and real-time PCR analyses (Figure 4A–B).
To evaluate the effects of KIF26B knockdown on CRC cell
proliferation, the expression of proliferation-related genes
(Ki67; cyclinD1) was detected by real-time PCR analysis). Overall survival of 88 patients in relation to KIF26B expression levels
ing of tissue microarrays. OS is significantly lower in patients with
s with tumors expressing low levels of both KIF26B and Ki67 (C).
Table 3 Univariate and multivariate analysis of overall survival
Univariate analysis Multivariate analysis









Others 0.470(0.259-0.852) 0.013* 0.501(0.272-0.922) 0.026*
Tumor size (cm)
< 5 1
≥ 5 1.801(0.993-3.267) 0.053
AJCC stage
I + II 1 1
III + IV 3.106(1.701-5.671) <0.001* 82.935(13.868-495.998) <0.001*
T stage
T1 + T2 1
T3 + T4 1.662(0.514-5.370) 0.396
N stage
N0 1 1
N1 + N2 3.106(1.701-5.671) <0.001* 2.558(1.355-4.828) 0.004*
M stage
M0 1 1
M1 10.801(2.448-47.658) 0.002* 77.710(13.384-451.213) <0.001*
Differentiation




Yes 6.188(2.093-18.295) <0.001* 1.111(0.246-5.019) 0.892
KIF26B
Low 1 1
High 5.311(2.360-11.952) <0.001* 5.621(2.302-13.730) <0.001*
Ki67
Low 1 1
High 2.343(1.254-4.377) 0.008* 1.433(0.718-2.860) 0.307
*indicates P<0.05.
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mRNA was downregulated in KIF26B-shRNA cells.
Next, we performed CCK-8 and plate colony formation
assays to assess the role of KIF26B in CRC cell growth
(Figure 4C–D). As shown in Figure 4C, KIF26B knock-
down was associated with significantly decreased cellproliferation compared with that of control-shRNA
cells. Furthermore, KIF26B knockdown in CRC cells
consistently reduced the colony formation ability com-
pared with control-shRNA cells (P < 0.01). These
results indicated that KIF26B plays a role in CRC
cell proliferation.
Figure 4 KIF26B knockdown inhibits cancer cell proliferation. Western blot analysis of KIF26B protein expression in stable knockdown RKO
and HT29 cell lines. Grayscale values were evaluated (n = 3, *P <0.05) (A). Expression of proliferation-related genes was inhibited in KIF26B knockdown
cells according to real-time PCR analysis (n = 3; *P < 0.05) (B). Effects of KIF26B knockdown on cell growth was evaluated by Cell Counting Kit-8 assays
(C) and plate colony formation assays (D) (n = 3; *P < 0.05).
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Numerous studies have shown that the abnormal ex-
pression and function of kinesins plays a key role in the
development and progression of many human cancers
[16,17]. KIF26B comprises 2,108 amino acids, with a
predicted molecular weight of 223.8 kDa. In mice,
KIF26B plays a role in embryogenesis, specifically in the
development of limbs, faces, and somites [26]. KIF26B
also plays an important role in kidney development and
is involved in the development and progression of sometypes of tumors, including breast cancer, esophageal
adenocarcinoma, and colorectal adenomatous polyposis
[19,22-24]. However, studies on KIF26B expression dur-
ing tumorigenesis and progression of CRC are rare.
The present study showed for the first time that both
KIF26B mRNA and protein expression are upregulated
in primary CRC tissues. In the immunohistochemical
analysis, high KIF26B expression in colorectal cancer tis-
sues was significantly associated with other malignant
tumor characteristics, such as larger tumor size, AJCC
Wang et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:13 Page 9 of 10stage, tumor depth, differentiation histology, and lymph
node metastasis, implicating KIF26B as a biomarker of
malignant tumors. Ki67 is one of the most commonly
used markers to evaluate the proliferation of tumor cells
and has prognostic value in some types of cancer
[27-30]. In our study, we found that high KIF26B expres-
sion correlated positively with Ki67 expression, suggest-
ing that KIF26B is involved in tumor cell proliferation.
Given that kinesins are involved in mitosis, KIFs have
attracted significant attention in the search for novel, al-
ternative mitotic drug targets of cancer [31-33]. Several
KIF11-inihibitors have entered Phase I or Phase II clin-
ical trials either in combination with other drugs or as
monotherapies [16]. Vaccination with a KIF20A-derived
peptide in combination with gemcitabine is a feasible
and promising approach to the treatment of advanced
pancreatic cancer [34]. We hypothesized that knock-
down of KIF26B will reduce cancer cell proliferation and
is therefore, a potential therapeutic target. In this study,
investigation of the effect of KIF26B on CRC cell prolif-
eration in CCK-8 assays showed that KIF26B knockdown
in RKO and HT29 cells inhibited cell proliferation activ-
ity. In addition, expression of KIF26B and proliferation-
related genes (Ki67; cyclinD1) was shown to significantly
downregulated in KIF26B knockdown cells using quanti-
tative real-time PCR assays. Moreover, colony formation
ability was significantly reduced in KIF26B knockdown
cells. These data indicate that suppression of KIF26B in-
hibits cell proliferation and implicate KIF26B as a poten-
tial therapeutic target for CRC.
To date, the prognostic value of KIF26B expression in
CRC has not been reported. Our Kaplan-Meier survival
analysis demonstrated that high KIF26B expression is
significantly related to poor prognosis after surgical re-
section in CRC patients (P < 0.001). In our study, pa-
tients with elevated KIF26B expression were significantly
linked to poorer OS. Furthermore, Cox regression ana-
lysis suggested that KIF26B is an independent prognostic
factor, indicating that KIF26B is a new predictor to the
prognosis of patients with CRC.
It should be noted that there are some limitations of
our study. First, KIF26B overexpressing cell lines were
not investigated in our study. Despite repeated attempts,
we were unable to generate a KIF26B overexpression
plasmid because of the huge coding sequence (CDS,
6,315 bp, GeneBank, NM_018012). Second, the effects
of KIF26B knockdown were not investigated in vivo in
the present study. Third, further studies are required to
confirm our hypothesis that KIF26B is a potential target
for CRC therapy.
Conclusion
Taken together, our data indicate that KIF26B plays an
important role in CRC carcinogenesis, especially intumor development, progression and proliferation. Our
study demonstrates for the first time that KIF26B ex-
pression is elevated in CRC tissues at both the mRNA
and protein levels. Furthermore, KIF26B knockdown
inhibited cell proliferation in CRC cell lines. Moreover,
our study provides clinical evidence that KIF26B is an
independent prognostic indicator of outcome for CRC
patients; thus, KIF26B is implicated as a potential thera-
peutic target in CRC. Further investigations are required
to fully elucidate the role of KIF26B in the progression of
CRC and the potential of KIF26B as a therapeutic target.
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